Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper \[first toleration of solid food\] and lower \[first bowel movement\] gastrointestinal recovery) compared to placebo.

Trial Details

NCT ID
NCT03216525
Phase
PHASE3
Sponsor
Brigham and Women's Hospital
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Alvimopan
  • Placebo
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Patients undergoing radical cystectomy and urinary diversion via open or robotic approach.
  • Man or woman between the ages of 18 and 85.
  • American Society of Anesthesiologists (ASA) Physical Status Score of class 1-4
  • Ileal conduit or ileal neobladder urinary diversion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →